查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1784039

精準基因組檢測的全球市場

Precision Genomic Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 222 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計2030年全球精準基因組檢測市場規模將達423億美元

全球精準基因組檢測市場規模預計在2024年達到167億美元，預計在分析期內（2024-2030年）的複合年成長率為16.7%，到2030年將達到423億美元。基因組檢測耗材是本報告分析的細分市場之一，預計其複合年成長率為18.2%，至分析期末達246億美元。基因組檢測設備細分市場在分析期間內的複合年成長率預計為15.3%。

美國市場規模估計為 44 億美元，中國市場預計複合年成長率為 15.7%

美國精準基因組檢測市場規模預計在2024年達到44億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到65億美元，在2024-2030年的分析期間內，複合年成長率為15.7%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為15.6%和14.3%。在歐洲，預計德國市場的複合年成長率約為12.1%。

全球精準基因組檢測市場—主要趨勢與促進因素摘要

精準基因組檢測將如何改變醫療保健？

精準基因組檢測正在徹底改變現代醫學，它能夠實現個人化診斷、標靶治療和早期疾病檢測。透過分析個體的基因組成，醫療保健提供者可以根據基因變異制定個人化治療方案，從而顯著改善患者的預後。這種方法在腫瘤學、罕見疾病、藥物基因組學和生殖醫學領域尤其有效，因為基因洞察在這些領域的治療決策中發揮關鍵作用。

次世代定序儀(NGS)、基於 CRISPR 的基因編輯以及人工智慧主導的生物資訊學的擴展，正在加速精準基因組檢測在各個醫療領域的應用。全基因組定序 (WGS)、全外EXOME定序 (WES) 和液態切片技術的進步正在提高診斷準確性，並使基因組檢測更加便利且更具成本效益。隨著基因研究的不斷發展，包括蛋白質體學和代謝體學在內的多組體學的整合，正在進一步改善精準醫療的應用。

哪些市場趨勢正在推動精準基因組檢測的成長？

影響精準基因組檢測市場最重要的趨勢之一是個人化醫療需求的持續成長。人們日益認知到基因差異會影響藥物反應，這推動了藥物基因體學的擴展，該技術可根據個體的基因圖譜確定最有效的藥物。這在腫瘤學、循環系統和神經內科等領域尤其重要，因為遺傳因素會顯著影響治療結果。

另一個重要趨勢是直接面對消費者 (DTC) 的基因檢測日益普及。提供用於家譜、疾病風險評估和生活方式建議的家用基因組檢測套組的公司日益普及，並正在推動市場擴張。然而，監管監督和資料隱私方面的倫理問題仍然是該領域面臨的重大挑戰。

人工智慧和巨量資料分析的進步也正在改變基因組檢測的模式。機器學習演算法正被用於解讀海量基因組數據，從而提高疾病風險預測和生物標記發現的準確性。此外，雲端基礎的基因組資料庫正在促進大規模基因研究，加速複雜疾病和潛在治療標靶的研究。

哪些地區在精準基因組檢測上處於領先地位？

北美在精準基因組檢測市場佔據主導地位，這得益於雄厚的科研經費、個人化醫療的普及率以及先進的醫療基礎設施。美國憑藉其在基因組學研究方面的大量投入、「我們所有人」研究計劃等政府舉措以及生物技術公司與學術機構之間的合作，佔據了領先地位。

歐洲也是一個重要的參與者，得益於監管支持、官民合作關係以及人們對基因檢測臨床益處日益成長的認知。德國、英國和法國等國家正在推動精準醫療，重點是將基因組數據整合到醫療保健系統中，以改善病患照護。

受生物技術投資增加、醫療保健可近性擴大以及政府推動精準醫療舉措的推動，基因組檢測在亞太地區發展迅速。中國、日本和韓國均設有專門收集和分析基因組數據的國家項目，引領該地區的基因組研究工作。同時，拉丁美洲和中東等新興市場也逐步採用精準基因組檢測，但高昂的成本和有限的基礎設施仍是其廣泛應用的障礙。

精準基因組檢測市場的成長受多種因素驅動

市場成長的主要驅動力之一是癌症、神經退化性疾病、心血管疾病等遺傳和複雜疾病的盛行率不斷上升。隨著早期發現和風險評估在醫療保健中變得越來越重要，基因組檢測在指南預防措施和精準治療方面發揮著至關重要的作用。

定序平台的技術進步，例如經濟高效的超快速定序技術的開發，正在使基因組檢測更加便利。可攜式定序設備和自動化工作流程的出現，進一步擴大了精準醫療的覆蓋範圍，使其從專業實驗室延伸至臨床環境和照護現場診斷。

監管支持和資助措施也在加速市場應用。世界各國政府正在投資國家基因組資料庫和精準醫療項目，促進醫療保健提供者、研究機構和生物技術公司之間的合作。此外，基因檢測的報銷政策也不斷發展，提高了患者獲得基因組診斷服務的可負擔性和可近性。

隨著基因組學領域的不斷發展，人工智慧、雲端處理和分子生物學的融合將進一步提升精準基因組檢測的能力。該市場預計將重新定義疾病管理、藥物開發和預防性醫療保健，並有望實現顯著成長，塑造全球個人化醫療的未來。

部分

類型（基因組檢測耗材、基因組檢測設備、基因組檢測服務）、技術類型（二代定序技術、聚合酵素鏈鎖反應技術、微陣列技術、桑格定序技術、CRISPR/CAS系統技術、其他技術類型）、應用領域（腫瘤學應用、心血管疾病應用、神經科疾病應用、生殖醫學應用實驗室、罕見疾病應用、其他學術用途

受訪公司範例

  • 23andMe
  • Ambry Genetics
  • BGI Genomics
  • Centogene NV
  • Color Health, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine
  • Fulgent Genetics
  • GeneDx
  • Genomic Health（a subsidiary of Exact Sciences）
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Luminex Corporation
  • Myriad Genetics
  • Natera, Inc.
  • NeoGenomics Laboratories
  • Oxford Nanopore Technologies
  • Qiagen
  • Thermo Fisher Scientific

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

Global Industry Analysts 沒有遵循查詢 LLM 或特定產業SLM 的典型規範，而是建立了一個來自世界各地專家的精選內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 比賽

簡介目錄
Product Code: MCP32666

Global Precision Genomic Testing Market to Reach US$42.3 Billion by 2030

The global market for Precision Genomic Testing estimated at US$16.7 Billion in the year 2024, is expected to reach US$42.3 Billion by 2030, growing at a CAGR of 16.7% over the analysis period 2024-2030. Genomic Testing Consumables, one of the segments analyzed in the report, is expected to record a 18.2% CAGR and reach US$24.6 Billion by the end of the analysis period. Growth in the Genomic Testing Equipment segment is estimated at 15.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.4 Billion While China is Forecast to Grow at 15.7% CAGR

The Precision Genomic Testing market in the U.S. is estimated at US$4.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2030 trailing a CAGR of 15.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global Precision Genomic Testing Market - Key Trends & Drivers Summarized

How Is Precision Genomic Testing Transforming Healthcare?

Precision genomic testing is revolutionizing modern medicine by enabling personalized diagnostics, targeted therapies, and early disease detection. By analyzing an individual's genetic makeup, healthcare providers can tailor treatments based on genetic variations, significantly improving patient outcomes. This approach is particularly impactful in oncology, rare diseases, pharmacogenomics, and reproductive health, where genetic insights play a crucial role in treatment decisions.

The expansion of next-generation sequencing (NGS), CRISPR-based gene editing, and AI-driven bioinformatics has accelerated the adoption of precision genomic testing across various medical fields. Advances in whole genome sequencing (WGS), whole exome sequencing (WES), and liquid biopsy techniques are enhancing diagnostic accuracy, making genomic testing more accessible and cost-effective. As genetic research continues to evolve, the integration of multi-omics approaches-including proteomics and metabolomics-is further refining precision medicine applications.

What Market Trends Are Driving Growth in Precision Genomic Testing?

One of the most significant trends shaping the precision genomic testing market is the increasing demand for personalized medicine. The growing recognition that genetic differences influence drug response has fueled the expansion of pharmacogenomics, which helps determine the most effective medications for individuals based on their genetic profiles. This is particularly important in fields such as oncology, cardiology, and neurology, where genetic factors significantly impact treatment efficacy.

Another key trend is the rising adoption of direct-to-consumer (DTC) genetic testing. Companies offering at-home genomic testing kits for ancestry, disease risk assessment, and lifestyle recommendations have gained popularity, driving market expansion. However, regulatory scrutiny and ethical concerns regarding data privacy remain key challenges in this sector.

Advancements in AI and big data analytics are also transforming the genomic testing landscape. Machine learning algorithms are being used to interpret vast amounts of genomic data, improving the accuracy of disease risk prediction and biomarker discovery. Additionally, cloud-based genomic databases are facilitating large-scale genetic studies, accelerating research into complex diseases and potential therapeutic targets.

Which Regions Are Leading in Precision Genomic Testing Adoption?

North America dominates the precision genomic testing market, driven by strong research funding, high adoption of personalized medicine, and advanced healthcare infrastructure. The United States leads the way with significant investments in genomics research, government initiatives such as the All of Us Research Program, and collaborations between biotech firms and academic institutions.

Europe is also a key player, benefiting from regulatory support, public-private partnerships, and growing awareness of genetic testing’s clinical benefits. Countries like Germany, the UK, and France are advancing precision medicine initiatives, with an emphasis on integrating genomic data into healthcare systems to improve patient care.

Asia-Pacific is experiencing rapid growth in genomic testing, fueled by increasing investments in biotechnology, expanding healthcare access, and government initiatives promoting precision medicine. China, Japan, and South Korea are leading the region’s genomic research efforts, with national programs dedicated to genomic data collection and analysis. Meanwhile, emerging markets in Latin America and the Middle East are gradually adopting precision genomic testing, although challenges such as high costs and limited infrastructure remain barriers to widespread implementation.

The Growth in the Precision Genomic Testing Market Is Driven by Several Factors

One of the primary drivers of market growth is the increasing prevalence of genetic disorders and complex diseases such as cancer, neurodegenerative conditions, and cardiovascular diseases. As early detection and risk assessment become more critical in healthcare, genomic testing is playing an essential role in guiding preventative measures and precision therapies.

Technological advancements in sequencing platforms, including the development of cost-efficient and ultra-fast sequencing techniques, are making genomic testing more accessible. The emergence of portable sequencing devices and automated workflows is further expanding the reach of precision medicine beyond specialized laboratories to clinical settings and point-of-care diagnostics.

Regulatory support and funding initiatives are also accelerating market adoption. Governments worldwide are investing in national genomic databases and precision medicine programs, promoting collaboration between healthcare providers, research institutions, and biotech companies. Additionally, reimbursement policies for genetic testing are evolving, improving affordability and patient access to genomic-based diagnostics.

As the field of genomics continues to advance, the convergence of AI, cloud computing, and molecular biology will further enhance the capabilities of precision genomic testing. With its potential to redefine disease management, drug development, and preventative healthcare, the market is poised for substantial growth, shaping the future of personalized medicine worldwide.

SCOPE OF STUDY:

The report analyzes the Precision Genomic Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Genomic Testing Consumables, Genomic Testing Equipment, Genomic Testing Services); Technology Type (Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology, Other Technology Types); Application (Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application, Other Applications); End-Use (Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • 23andMe
  • Ambry Genetics
  • BGI Genomics
  • Centogene N.V.
  • Color Health, Inc.
  • Exact Sciences Corporation
  • Foundation Medicine
  • Fulgent Genetics
  • GeneDx
  • Genomic Health (a subsidiary of Exact Sciences)
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Luminex Corporation
  • Myriad Genetics
  • Natera, Inc.
  • NeoGenomics Laboratories
  • Oxford Nanopore Technologies
  • Qiagen
  • Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Precision Genomic Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Personalized Medicine Accelerates Adoption of Precision Genomic Testing
    • Increasing Awareness of Genetic Risk Factors for Disease Drives Growth in Precision Genomic Testing Applications
    • Surge in Preventive Healthcare and Early Disease Detection Expands Market Opportunity for Genomic Testing Solutions
    • Technological Advancements in CRISPR and Gene Editing Propel the Growth of Precision Genomic Testing
    • Growth in Direct-to-Consumer Genetic Testing Services Generates New Market Opportunities for Genomic Testing Providers
    • Rising Prevalence of Chronic Diseases and Cancer Accelerates Demand for Genomic Testing in Disease Prevention
    • Expansion of Genomic Research and Advancements in Bioinformatics Drives Innovation in Precision Genomic Testing
    • Increased Investment in Genomic Data Integration Technologies Strengthens the Case for Genomic Testing in Healthcare
    • Growing Focus on Pharmacogenomics and Tailored Drug Therapies Expands Market Demand for Genomic Testing Solutions
    • Rising Healthcare Expenditure Globally Accelerates Adoption of Precision Genomic Testing in Clinical Practice
    • Growing Popularity of Genetic Testing for Ancestry and Health Traits Drives Market Expansion
    • Integration of Artificial Intelligence and Machine Learning in Genomic Data Analysis Strengthens Adoption of Precision Genomic Testing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Precision Genomic Testing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Precision Genomic Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Precision Genomic Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Genomic Testing Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Genomic Testing Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Genomic Testing Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Genomic Testing Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Genomic Testing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Genomic Testing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Cardiovascular Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Cardiovascular Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Neurological Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Neurological Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Reproductive Health Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Reproductive Health Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Rare Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Rare Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Research & Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Next-Generation Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Next-Generation Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Polymerase Chain Reaction Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Microarray Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Microarray Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Sanger Sequencing Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Sanger Sequencing Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for CRISPR / CAS Systems Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World 6-Year Perspective for CRISPR / CAS Systems Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Other Technology Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 41: World 6-Year Perspective for Other Technology Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 42: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 46: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: USA 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 48: USA Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: USA 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Canada 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 54: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Canada 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • JAPAN
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Japan 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Japan 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 64: Japan Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Japan 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • CHINA
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 66: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: China 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 70: China Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: China 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 72: China Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: China 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • EUROPE
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for Precision Genomic Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Europe 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Europe 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 82: Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Europe 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • FRANCE
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 84: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: France 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 88: France Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: France 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 90: France Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: France 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • GERMANY
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Germany 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 96: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Germany 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • ITALY
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Italy 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Italy 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 106: Italy Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Italy 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • UNITED KINGDOM
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 108: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: UK 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 112: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: UK 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 114: UK Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: UK 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Rest of Europe 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Precision Genomic Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Asia-Pacific 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Type - Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of World 6-Year Perspective for Precision Genomic Testing by Type - Percentage Breakdown of Value Sales for Genomic Testing Consumables, Genomic Testing Equipment and Genomic Testing Services for the Years 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Application - Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World 6-Year Perspective for Precision Genomic Testing by Application - Percentage Breakdown of Value Sales for Oncology Application, Cardiovascular Diseases Application, Neurological Disorders Application, Reproductive Health Application, Rare Diseases Application and Other Applications for the Years 2025 & 2030
    • TABLE 136: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by End-Use - Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of World 6-Year Perspective for Precision Genomic Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use, Research & Academic Institutes End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 138: Rest of World Recent Past, Current & Future Analysis for Precision Genomic Testing by Technology Type - Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of World 6-Year Perspective for Precision Genomic Testing by Technology Type - Percentage Breakdown of Value Sales for Next-Generation Sequencing Technology, Polymerase Chain Reaction Technology, Microarray Technology, Sanger Sequencing Technology, CRISPR / CAS Systems Technology and Other Technology Types for the Years 2025 & 2030

IV. COMPETITION